<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2021-6.5.18</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-3049</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФТИЗИАТРИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHTHISIOLOGY</subject></subj-group></article-categories><title-group><article-title>Патогенетическая роль фактора некроза опухолей (TNF-α) для развития туберкулёза брюшины в эксперименте</article-title><trans-title-group xml:lang="en"><trans-title>Pathogenetic role of tumor necrosis factor (TNF-α) for the development of peritoneal tuberculosis in an experiment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6659-7888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плоткин</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Plotkin</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, доцент, врач-хирург, 107014, г. Москва, ул. Стромынка, 10;</p><p>доцент кафедры общей хирургии, 117997, г. Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Cand. Sc. (Med), Associate Professor, Surgeon, Stromynka str. 10, Moscow 107014;</p><p>Assistant Professor at the Department of Surgery, Ostrovityanova str. 1, Moscow 117997</p></bio><email xlink:type="simple">kn13@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5234-349X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виноградова</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinogradova</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, главный научный сотрудник, заведующая лабораторией экспериментального туберкулёза, </p><p>191036, г. Санкт-Петербург, Лиговский пр., 2-4</p></bio><bio xml:lang="en"><p>Dr. Sc. (Med.), Professor, Chief Research Officer, Head of the Laboratory of Experimental Tuberculosis,</p><p>Ligovsky ave. 2-4, St. Petersburg 191036</p></bio><email xlink:type="simple">vinogradova@spbniif.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4418-4601</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетников</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetnikov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, врач-хирург, </p><p>107014, г. Москва, ул. Стромынка, 10</p></bio><bio xml:lang="en"><p>Cand. Sc. (Med.), Surgeon,</p><p>Stromynka str. 10, Moscow 107014</p></bio><email xlink:type="simple">taxol@bk.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2814-4826</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зюзя</surname><given-names>Ю. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Zyuzya</surname><given-names>Yu. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулёза и патоморфологии, врач-патологоанатом,</p><p>107014, г. Москва, ул. Стромынка, 10</p></bio><bio xml:lang="en"><p>Cand. Sc. (Med.), Leading Research Officer at the Department of Problems of Laboratory Diagnostics of Tuberculosis and Pathomorphology, Pathologist, </p><p>Stromynka str. 10, Moscow 107014</p></bio><email xlink:type="simple">zuzaju@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4294-5531</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Оковитый</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Okovityi</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой фармакологии и клинической фармакологии, </p><p>197376, г. СанктПетербург, ул. Профессора Попова, 14, лит. А</p></bio><bio xml:lang="en"><p>Dr. Sc. (Med.), Professor, Head of the Department of Pharmacology and Clinical Pharmacology, </p><p>Professora Popova str. 14, lit. A, St. Petersburg 197376</p></bio><email xlink:type="simple">okovityy@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8951-5219</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Синицын</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sinitsyn</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, заместитель директора, </p><p>107014, г. Москва, ул. Стромынка, 10</p></bio><bio xml:lang="en"><p> Dr. Sc. (Med.), Deputy Director, </p><p>Stromynka str. 10, Moscow 107014</p></bio><email xlink:type="simple">msinitsyn@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1978-3722</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гайтукаев</surname><given-names>В. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gaitukaev</surname><given-names>V. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач клинический фармаколог, директор департамента клинических исследований, </p><p>105554, г. Москва, ул. 9-я Парковая, 8А</p></bio><bio xml:lang="en"><p>doctor clinical pharmacologist, Director of the Department of Clinical Research,</p><p>9-ya Parkovaya str. 8A, Moscow 105554</p></bio><email xlink:type="simple">vgaitukaev@ollamed.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6692-1425</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Родоман</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rodoman</surname><given-names>G. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой общей хирургии, </p><p>117997, г. Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Dr. Sc. (Med.), Professor, Head of the Department of Surgery,</p><p>Ostrovityanova str. 1, Moscow 117997</p></bio><email xlink:type="simple">gkb24@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4552-5022</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богородская</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogorodskaya</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> доктор медицинских наук, профессор, директор,</p><p>107014, г. Москва, ул. Стромынка, 10</p></bio><bio xml:lang="en"><p>Dr. Sc. (Med.), Professor, Director,</p><p>Stromynka str. 10, Moscow 107014</p></bio><email xlink:type="simple">BogorodskayaEM@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4385-9643</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яблонский</surname><given-names>П. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Yablonskiy</surname><given-names>P. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, директор, </p><p>191036, г. Санкт-Петербург, Лиговский пр., 2-4</p></bio><bio xml:lang="en"><p>Dr. Sc. (Med.), Professor, Director,</p><p>Ligovsky ave. 2-4, St. Petersburg 191036</p></bio><email xlink:type="simple">glhirurg2@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Московский городской научно-практический центр борьбы с туберкулёзом Департамента здравоохранения г. Москвы»;&#13;
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России</institution></aff><aff xml:lang="en"><institution>Moscow Research and Clinical Center for TB Control, Moscow Healthcare Department;&#13;
Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии» Минздрава России</institution></aff><aff xml:lang="en"><institution>Saint Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ «Московский городской научно-практический центр борьбы с туберкулёзом Департамента здравоохранения г. Москвы»</institution></aff><aff xml:lang="en"><institution>Moscow Research and Clinical Center for TB Control, Moscow Healthcare Department</institution></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный химикофармацевтический университет» Минздрава России</institution></aff><aff xml:lang="en"><institution>Saint Petersburg State Chemical Pharmaceutical University of the Ministry of Healthcare of the Russian Federation</institution></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ООО «ОЛЛА-МЕД»</institution></aff><aff xml:lang="en"><institution>OLLA-MED Company</institution></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России</institution></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2021</year></pub-date><volume>6</volume><issue>5</issue><fpage>184</fpage><lpage>195</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Плоткин Д.В., Виноградова Т.И., Решетников М.Н., Зюзя Ю.Р., Оковитый С.В., Синицын М.В., Гайтукаев В.Р., Родоман Г.В., Богородская Е.М., Яблонский П.К., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Плоткин Д.В., Виноградова Т.И., Решетников М.Н., Зюзя Ю.Р., Оковитый С.В., Синицын М.В., Гайтукаев В.Р., Родоман Г.В., Богородская Е.М., Яблонский П.К.</copyright-holder><copyright-holder xml:lang="en">Plotkin D.V., Vinogradova T.I., Reshetnikov M.N., Zyuzya Y.R., Okovityi S.V., Sinitsyn M.V., Gaitukaev V.R., Rodoman G.V., Bogorodskaya E.M., Yablonskiy P.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/3049">https://www.actabiomedica.ru/jour/article/view/3049</self-uri><abstract><p>Туберкулёз в настоящее время рассматривается как группа заболеваний, объединённых одним этиологическим фактором. Патогенез отдельных локализаций туберкулёзного воспаления, в частности туберкулёз брюшины, ещё недостаточно изучен. Роль цитокиновых механизмов в развитии заболевания и формировании нестерильного иммунитета требует дальнейших экспериментальных исследований, в частности создания воспроизводимой модели на лабораторных животных.</p><sec><title>Цель исследования</title><p>Цель исследования: изучить влияние TNF-α на развитие туберкулёза серозного покрова брюшной полости, а также оценить возможность моделирования туберкулёзного перитонита у лабораторных животных с помощью инфликсимаба.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследования проведены на 18  кроликах-самцах, которым моделировали туберкулёз брюшины с помощью внутрибрюшного введения суспензии Mycobacterium tuberculosis. Десяти кроликам экспериментальной группы за сутки до инфицирования вводили внутривенно раствор инфликсимаба и внутрибрюшинно железа (III) гидроксид сахарозный комплекс.</p></sec><sec><title>Результаты</title><p>Результаты. У животных контрольной группы туберкулёз либо не развивался, либо в трети случаев поражал только лёгочную паренхиму, при этом преобладали пролиферативные процессы. У животных с инактивированным TNF-α, напротив, в 100 % наблюдений обнаруживали туберкулёзный перитонит с содружественным поражением лёгких и преобладанием альтеративных казеозных процессов.</p></sec><sec><title>Заключение</title><p>Заключение. Созданная модель туберкулёзного перитонита показывает ведущую роль TNF-α в активации макрофагов, а также в привлечении клеток к месту инфекции. Это первичный сигнал, необходимый для формирования и устойчивости гранулём, поскольку нейтрализация этого цитокина приводит к потере контроля над инфекцией и разрушению гранулёмы с развитием деструктивного туберкулёза в серозном покрове брюшной полости. </p></sec></abstract><trans-abstract xml:lang="en"><p>Currently tuberculosis is considered as a group of diseases united by one etiological factor. The pathogenesis of certain localizations of tuberculous inflammation, in particular peritoneum tuberculosis, hasn’t been sufficiently studied. The role of cytokine mechanisms in the development of the disease and the elaboration of non-sterile immunity requires further experimental studies, in particular the creation of a reproducible model on laboratory animals.</p><sec><title>The aim</title><p>The aim: to study the effect of TNF-α on the development of tuberculosis of the serous coat of the abdominal cavity, as well as to evaluate the possibility of modeling tuberculous peritonitis in laboratory animals using infliximab.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The studies were conducted on 18 male rabbits, which were simulated peritoneal tuberculosis by intra-abdominal administration of a suspension of Mycobacterium tuberculosis. 10 rabbits of the experimental group were intravenously injected with an infliximab solution and an iron (III) hydroxide sucrose complex intraperitoneally a day before infection.</p></sec><sec><title>Results</title><p>Results. In the control group of animals, tuberculosis either didn’t develop, or in a third of cases it affected only the pulmonary parenchyma, while proliferative processes prevailed. On the contrary, in animals with inactivated TNF-α, in 100 % of observations, tuberculous peritonitis was detected with associated lung damage and the predominance of alterative caseous processes.</p></sec><sec><title>Conclusion</title><p>Conclusion. The created model of tuberculous peritonitis shows the leading role of TNF-α in the activation of macrophages, as well as in attracting cells to the site of infection. This is the primary signal necessary for the formation and stability of granulomas since the neutralization of this cytokine leads to a loss of control over the infection and the destruction of the granuloma with the development of destructive tuberculosis in the serous coat of the abdominal cavity. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>туберкулёзный перитонит</kwd><kwd>кролик</kwd><kwd>фактор некроза опухолей</kwd><kwd>модель туберкулёзного перитонита</kwd><kwd>инфликсимаб</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tuberculous peritonitis</kwd><kwd>rabbit</kwd><kwd>tumor necrosis factor</kwd><kwd>model of tuberculous peritonitis</kwd><kwd>infliximab</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jagger A, Reiter-Karam S, Hamada Y, Getahun H. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ. 2018; 96(3): 173-184F. doi: 10.2471/BLT.17.199414</mixed-citation><mixed-citation xml:lang="en">Jagger A, Reiter-Karam S, Hamada Y, Getahun H. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ. 2018; 96(3): 173-184F. doi: 10.2471/BLT.17.199414</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013; 31: 475-527. doi: 10.1146/annurev-immunol-032712-095939</mixed-citation><mixed-citation xml:lang="en">O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013; 31: 475-527. doi: 10.1146/annurev-immunol-032712-095939</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001; 19: 93-129. doi: 10.1146/annurev.immunol.19.1.93</mixed-citation><mixed-citation xml:lang="en">Flynn  JL, Chan  J. Immunology of tuberculosis. Annu Rev Immunol. 2001; 19: 93-129. doi: 10.1146/annurev.immunol.19.1.93</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell. 2009; 136(1): 37-49. doi: 10.1016/j.cell.2008.11.014</mixed-citation><mixed-citation xml:lang="en">Davis  JM, Ramakrishnan  L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell. 2009; 136(1): 37-49. doi: 10.1016/j.cell.2008.11.014</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc. 2007; 12(1): 22-25. doi: 10.1038/sj.jidsymp.5650027</mixed-citation><mixed-citation xml:lang="en">Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc. 2007; 12(1): 22-25. doi: 10.1038/sj.jidsymp.5650027</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol. 2000; 164(4): 2016-2020. doi: 10.4049/jimmunol.164.4.2016</mixed-citation><mixed-citation xml:lang="en">Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol. 2000; 164(4): 2016-2020. doi: 10.4049/jimmunol.164.4.2016</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mezouar S, Diarra I, Roudier J, Desnues B, Mege JL. Tumor necrosis factor-alpha antagonist interferes with the formation of granulomatous multinucleated giant cells: New insights into Mycobacterium tuberculosis infection. Front Immunol. 2019; 10: 1947. doi: 10.3389/fimmu.2019.01947</mixed-citation><mixed-citation xml:lang="en">Mezouar S, Diarra I, Roudier J, Desnues B, Mege JL. Tumor necrosis factor-alpha antagonist interferes with the formation of  granulomatous multinucleated giant cells: New insights into Mycobacterium tuberculosis infection. Front Immunol. 2019; 10: 1947. doi: 10.3389/fimmu.2019.01947</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: A systematic review and meta-analysis of randomized controlled trials. BMJ Open. 2017; 7(3): e012567. doi: 10.1136/bmjopen-2016-012567</mixed-citation><mixed-citation xml:lang="en">Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: A systematic review and meta-analysis of randomized controlled trials. BMJ Open. 2017; 7(3): e012567. doi: 10.1136/bmjopen-2016-012567</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Е.В., Лобанова Н.В., Яхин И.Р., Романова Н.А., Серегин Ю.А. Роль фактора некроза опухолей-альфа в иммунопатогенезе заболеваний различной этиологии и его значимость в развитии антицитокиновой терапии моноклональными антителами. Медицинская иммунология. 2018; 20(6): 797-806. doi: 10.15789/1563-0625-2018-6-797-806</mixed-citation><mixed-citation xml:lang="en">Voronina  EV, Lobanova  NV, Yakhin  IR, Romanova  NA, Seregin YuA. The role of tumor necrosis factor-alpha in the immunopathogenesis of diseases of various etiologies and its significance in the development of anti-cytokine therapy with monoclonal antibodies. Medical Immunology (Russia). 2018; 20(6): 797-806. (In Russ.). doi: 10.1183/09031936.00028510</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Infection risk associated with anti-TNF-α agents: A review. Expert Opin Drug Saf. 2015; 14(4): 571-582. doi: 10.1517/14740338.2015.1009036</mixed-citation><mixed-citation xml:lang="en">Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Infection risk associated with anti-TNF-α agents: A review. Expert Opin Drug Saf. 2015; 14(4): 571-582. doi: 10.1517/14740338.2015.1009036</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002; 301(2): 418-426. doi: 10.1124/jpet.301.2.418</mixed-citation><mixed-citation xml:lang="en">Scallon  B, Cai  A, Solowski  N, Rosenberg  A, Song  XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002; 301(2): 418-426. doi: 10.1124/jpet.301.2.418</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Борисов С.Е., Лукина Г.В., Слогоцкая Л.В., Кочетков Я.А., Гунтупова Л.Д., Куликовская Н.В. Скрининг и мониторинг туберкулёзной инфекции у ревматологических больных, получающих генно-инженерные биологические препараты. Туберкулёз и болезни лёгких. 2011; 88(6): 42-50.</mixed-citation><mixed-citation xml:lang="en">Borisov  SE, Lukina  GV, Slogotskaya  LV, Kochetkov YaA, Guntupova LD, Kulikovskaya NV. Tuberculosis infection screening and monitoring in rheumatic patients receiving gene engineering biological. Tuberculosis and Lung Diseases. 2011; 88(6): 42-50. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspasedependent pathway. Gastroenterology. 2001; 121(5): 1145-1157. doi: 10.1053/gast.2001.28702</mixed-citation><mixed-citation xml:lang="en">Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspasedependent pathway. Gastroenterology. 2001; 121(5): 1145-1157. doi: 10.1053/gast.2001.28702</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med. 2016; 12(3): 1693-1704. doi: 10.3892/etm.2016.3548</mixed-citation><mixed-citation xml:lang="en">Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A  meta-analysis. Exp Ther Med. 2016; 12(3): 1693-1704. doi: 10.3892/etm.2016.3548</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol. 2003; 171(6): 3110-3118. doi: 10.4049/jimmunol.171.6.3110</mixed-citation><mixed-citation xml:lang="en">Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol. 2003; 171(6): 3110-3118. doi: 10.4049/jimmunol.171.6.3110</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, Fuhrman C, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum. 2010; 62(2): 340-350. doi: 10.1002/art.27271</mixed-citation><mixed-citation xml:lang="en">Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, Fuhrman C, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum. 2010; 62(2): 340-350. doi: 10.1002/art.27271</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Capuano SV 3rd, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M.tuberculosis infection. Infect Immun. 2003; 71(10): 5831-5844. doi: 10.1128/IAI.71.10.5831-5844.2003</mixed-citation><mixed-citation xml:lang="en">Capuano SV 3rd, Croix DA, Pawar S, Zinovik A, Myers A, Lin  PL, et  al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M.tuberculosis infection. Infect Immun. 2003; 71(10): 5831-5844. doi: 10.1128/IAI.71.10.5831-5844.2003</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tsenova L, O’Brien P, Holloway J, Peixoto B, Soteropoulos P, Fallows D, et al. Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis. J Interferon Cytokine Res. 2014; 34(9): 716-726. doi: 10.1089/jir.2013.0123</mixed-citation><mixed-citation xml:lang="en">Tsenova L, O’Brien P, Holloway J, Peixoto B, Soteropoulos P, Fallows D, et al. Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis. J Interferon Cytokine Res. 2014; 34(9): 716-726. doi: 10.1089/jir.2013.0123</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Vaid U, Kane GC. Tuberculous peritonitis. Microbiol Spectr. 2017; 5(1). doi: 10.1128/microbiolspec.TNMI7-0006-2016</mixed-citation><mixed-citation xml:lang="en">Vaid U, Kane GC. Tuberculous peritonitis. Microbiol Spectr. 2017; 5(1). doi: 10.1128/microbiolspec.TNMI7-0006-2016</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Srivastava U, Almusa O, Tung KW, Heller MT. Tuberculous peritonitis. Radiol Case Rep. 2015; 9(3): 971. doi: 10.2484/rcr.v9i3.971</mixed-citation><mixed-citation xml:lang="en">Srivastava U, Almusa O, Tung KW, Heller MT. Tuberculous peritonitis. Radiol Case Rep. 2015; 9(3): 971. doi: 10.2484/rcr.v9i3.971</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">ГОСТ 33216-2014. Правила работы с лабораторными грызунами и кроликами. М.: Стандартинформ; 2016.</mixed-citation><mixed-citation xml:lang="en">GOST 33216-2014. Rules for working with laboratory rodents and rabbits. Moscow, Standartinform; 2016. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Шекунова Е.В., Ковалева М.А., Макарова М.Н., Макаров В.Г. Выбор дозы препарата для доклинического исследования: межвидовой перенос доз. Ведомости Научного центра экспертизы средств медицинского применения. 2020; 10(1): 19-28. doi: 10.30895/1991-2919-2020-10-1-19-28</mixed-citation><mixed-citation xml:lang="en">Shekunova EV, Kovaleva MA, Makarova MN, Makarov VG. Dose selection in preclinical studies: Cross-species dose conversion. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2020; 10(1): 19-28. (in Russ.). doi: 10.30895/1991-2919-2020-10-1-19-28</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Nairz M, Theurl I, Swirski FK, Weiss G. “Pumping iron” – how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch. 2017; 469(3-4): 397-418. doi: 10.1007/s00424-017-1944-8</mixed-citation><mixed-citation xml:lang="en">Nairz M, Theurl I, Swirski FK, Weiss G. “Pumping iron” – how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch. 2017; 469(3-4): 397-418. doi: 10.1007/s00424-017-1944-8</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Найманов А.Х., Гулюкин А.М., Толстенко Н.Г., Вангели Е.П., Калмыков В.М. Проба с диаскинтестом при диагностике туберкулёза животных. Туберкулёз и болезни лёгких. 2020; 98(12): 53-56. doi: 10.21292/2075-1230-2020-98-12-53-56</mixed-citation><mixed-citation xml:lang="en">Naymanov AKh, Gulyukin AM, Tolstenko NG, Vangeli EP, Kalmykov VM Diaskintest for the diagnosis of bovine tuberculosis. Tuberculosis and Lung Diseases. 2020; 98(12): 53-56. (In Russ.). doi: 10.21292/2075-1230-2020-98-12-53-56</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Шепелькова Г.С., Евстифеев В.В., Апт А.С. Исследование молекулярных механизмов патогенеза туберкулёза на экспериментальных моделях. Туберкулёз и болезни лёгких. 2012; 89(7): 3-11.</mixed-citation><mixed-citation xml:lang="en">Shepelkova GS, Evstifeev VV, Apt AS. Study of molecular mechanisms of the pathogenesis of tuberculosis in experimental models. Tuberculosis and Lung Diseases. 2012; 89(7): 3-11. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Fonseca KL, Rodrigues PNS, Olsson IAS, Saraiva M. Experimental study of tuberculosis: From animal models to complex cell systems and organoids. PLoS Pathog. 2017; 13(8): e1006421. doi: 10.1371/journal.ppat.1006421</mixed-citation><mixed-citation xml:lang="en">Fonseca  KL, Rodrigues  PNS, Olsson  IAS, Saraiva  M. Experimental study of tuberculosis: From animal models to complex cell systems and organoids. PLoS Pathog. 2017; 13(8): e1006421. doi: 10.1371/journal.ppat.1006421</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Найманов А.Х., Калмыков В.М., Калмыкова М.С. Воспроизведение туберкулёза на лабораторных животных (биологическая проба). Ветеринария, зоотехния и биотехнология. 2018; 5: 24-30.</mixed-citation><mixed-citation xml:lang="en">Naymanov AKh, Kalmykov VM, Kalmykova MS. Reproduction of tuberculosis in laboratory animals (bioassay). Veterinary, Zootechnics and Biotechnology. 2018; 5: 24-30. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gao J, Guo M, Teng L, Bao R, Xian Q, Wang X, et al. Guinea pig infected with Mycobacterium tuberculosis via oral consumption, J Appl Anim Res. 2018; 46(1): 1323-1328. doi: 10.1080/09712119.2018.1505622</mixed-citation><mixed-citation xml:lang="en">Gao J, Guo M, Teng L, Bao R, Xian Q, Wang X, et al. Guinea pig infected with Mycobacterium tuberculosis via oral consumption, J Appl Anim Res. 2018; 46(1): 1323-1328. doi: 10.1080/09712119.2018.1505622</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Рыбакова А.В., Макарова М.Н., Макаров В.Г. Использование кроликов в доклинических исследованиях. Международный вестник ветеринарии. 2016; 4: 102-106. 30. Lurie MB. The fate of human and bovine tubercle bacilli in various organs of the rabbit. J Exp Med. 1928; 48(2): 155-182. doi: 10.1084/jem.48.2.155</mixed-citation><mixed-citation xml:lang="en">Rybakova AV, Makarova MN, Makarov VG. Using rabbits in pre-clinical trials. International Bulletin of Veterinary Medicine. 2016; 4: 102-106. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Dorman SE, Hatem CL, Tyagi S, Aird K, Lopez-Molina J, Pitt ML, et al. Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits. Infect Immun. 2004; 72(3): 1700-1705. doi: 10.1128/IAI.72.3.1700-1705</mixed-citation><mixed-citation xml:lang="en">Lurie MB. The fate of human and bovine tubercle bacilli in various organs of the rabbit. J Exp Med. 1928; 48(2): 155-182. doi: 10.1084/jem.48.2.155</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15): 1098-1104. doi: 10.1056/NEJMoa011110</mixed-citation><mixed-citation xml:lang="en">Dorman  SE, Hatem  CL, Tyagi  S, Aird  K, Lopez-Molina  J, Pitt ML, et al. Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits. Infect Immun. 2004; 72(3): 1700-1705. doi: 10.1128/IAI.72.3.1700-1705</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002; 168(9): 4620-4627. doi: 10.4049/jimmunol.168.9.4620</mixed-citation><mixed-citation xml:lang="en">Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a  tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15): 1098-1104. doi: 10.1056/NEJMoa011110</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Park HJ, Choi BY, Sohn M, Han NY, Kim I, Oh JM. Effects of tumor necrosis factor-alpha inhibitors on the incidence of tuberculosis. Korean J Clin Pharm. 2018; 28: 333-341. doi: 10.24304/kjcp.2018.28.4.333</mixed-citation><mixed-citation xml:lang="en">Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002; 168(9): 4620-4627. doi: 10.4049/jimmunol.168.9.4620</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Сартаева Г.Ш., Исаева А.Г., Рахышева А.А. Особая роль фактора некроза опухоли-альфа в противотуберкулёзном ответе. Вестник Казахского Национального медицинского университета. 2018; 4: 69-73.</mixed-citation><mixed-citation xml:lang="en">Park HJ, Choi BY, Sohn M, Han NY, Kim I, Oh JM. Effects of tumor necrosis factor-alpha inhibitors on the incidence of tuberculosis. Korean J Clin Pharm. 2018; 28: 333-341. doi: 10.24304/kjcp.2018.28.4.333</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. 2008; 29(2): 283-294. doi: 10.1016/j.immuni.2008.06.011</mixed-citation><mixed-citation xml:lang="en">Sartaeva  GSh, Isaeva  AG, Rahysheva  AA. A special role of the tumor necrosis factor-alpha in the antitubercular response. Bulletin of the Kazakh National Medical University. 2018; 4: 69-73. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Clay  H, Volkman  HE, Ramakrishnan  L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. 2008; 29(2): 283-294. doi: 10.1016/j.immuni.2008.06.011</mixed-citation><mixed-citation xml:lang="en">Clay  H, Volkman  HE, Ramakrishnan  L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. 2008; 29(2): 283-294. doi: 10.1016/j.immuni.2008.06.011</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
